---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-007361"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:48:15.899563+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology reports Q4 2021 net loss $28.4M ($0.70/shr); cash $363.7M through mid-2024

## Summary
- GAAP net loss Q4 2021: $28.4M ($0.70/shr) vs $18.8M ($0.50/shr) year ago; full year loss $83.5M ($2.07/shr).
- R&D expenses Q4 $20.9M (incl. $4.7M ScalmiBio acquisition IPR&D) vs $12.1M year ago.
- Cash $363.7M at Dec 31, 2021; runway through mid-2024.
- FDA granted Orphan Drug Designation for evorpacept in gastric/GEJ cancer (Jan 2022).
- Plan to initiate randomized Phase 2/3 ASPEN-06 trial in 2nd line gastric/GEJ cancer in 2022.

## SEC filing metadata
- accession: 0001564590-22-007361
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000156459022007361/0001564590-22-007361-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000156459022007361/alxo-8k_20220228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-007361
- JSON: https://secwatch.observer/filing/0001564590-22-007361.json
- Plain text: https://secwatch.observer/filing/0001564590-22-007361.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.